Steven A Rosenberg

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma
    Melissa M Alvarez-Downing
    Surgery Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Building 10 Hatfield CRC, Room 3 5930, Bethesda, MD 20892 1201, USA
    World J Surg Oncol 10:113. 2012
  2. pmc IRF5 gene polymorphisms in melanoma
    Lorenzo Uccellini
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 10:170. 2012
  3. pmc Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor
    Robert P T Somerville
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Transl Med 10:69. 2012
  4. pmc Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma
    Jared J Gartner
    The Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
    BMC Genomics 13:505. 2012
  5. pmc New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer
    David F Stroncek
    Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA
    J Transl Med 10:48. 2012
  6. pmc Cancer immunotherapy: moving beyond current vaccines
    Steven A Rosenberg
    Surgery Branch of the Center for Cancer Research at the National Cancer Institute, Building 10, Room 2B42, 10 Center Drive, MSC 1502 Bethesda, Maryland 20892 1502, USA
    Nat Med 10:909-15. 2004
  7. pmc Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma
    Steven A Rosenberg
    Center for Cancer Research, Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 9:2973-80. 2003
  8. pmc Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    Giao Q Phan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:8372-7. 2003
  9. pmc Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens
    Giao Q Phan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892 1502, USA
    J Immunother 26:349-56. 2003
  10. pmc Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
    Laura A Johnson
    Surgery Branch, Hatfield Clinical Research Center, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Blood 114:535-46. 2009

Collaborators

Detail Information

Publications142 found, 100 shown here

  1. pmc Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma
    Melissa M Alvarez-Downing
    Surgery Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Building 10 Hatfield CRC, Room 3 5930, Bethesda, MD 20892 1201, USA
    World J Surg Oncol 10:113. 2012
    ..To increase the availability of this promising therapy in patients with advanced melanoma, a minimally invasive approach to procure tumor for TIL generation is warranted...
  2. pmc IRF5 gene polymorphisms in melanoma
    Lorenzo Uccellini
    Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and trans NIH Center for Human Immunology, National Institutes of Health, Bethesda, MD 20892, USA
    J Transl Med 10:170. 2012
    ....
  3. pmc Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor
    Robert P T Somerville
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Transl Med 10:69. 2012
    ..To simplify clinical scale lymphocyte expansions, we investigated the use of the WAVE®, a closed system bioreactor that utilizes active perfusion to generate high cell numbers in minimal volumes...
  4. pmc Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma
    Jared J Gartner
    The Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
    BMC Genomics 13:505. 2012
    ..Here we performed whole exome sequencing of two sets of matched normal and metastatic tumor DNAs...
  5. pmc New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer
    David F Stroncek
    Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA
    J Transl Med 10:48. 2012
    ..In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies...
  6. pmc Cancer immunotherapy: moving beyond current vaccines
    Steven A Rosenberg
    Surgery Branch of the Center for Cancer Research at the National Cancer Institute, Building 10, Room 2B42, 10 Center Drive, MSC 1502 Bethesda, Maryland 20892 1502, USA
    Nat Med 10:909-15. 2004
    ..6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models...
  7. pmc Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma
    Steven A Rosenberg
    Center for Cancer Research, Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 9:2973-80. 2003
    ..The immunogenicity of these constructs was studied using peripheral blood mononuclear cells to measure epitope-specific release of IFN-gamma...
  8. pmc Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    Giao Q Phan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:8372-7. 2003
    ..This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy...
  9. pmc Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens
    Giao Q Phan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892 1502, USA
    J Immunother 26:349-56. 2003
    ..Moreover, the sequential, nonrandomized nature of patient enrollment for the two trials may account for the differences in immunologic response...
  10. pmc Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
    Laura A Johnson
    Surgery Branch, Hatfield Clinical Research Center, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Blood 114:535-46. 2009
    ..This trial was registered at www.ClinicalTrials.gov as NCI-07-C-0174 and NCI-07-C-0175...
  11. pmc Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
    Mark E Dudley
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892 1201, USA
    J Clin Oncol 26:5233-9. 2008
    ..Here, we update that study and evaluate the safety and efficacy of two increased-intensity myeloablative lymphodepleting regimens...
  12. pmc High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens
    Richard A Morgan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 171:3287-95. 2003
    ..These results suggest that lymphocytes genetically engineered to express anti-gp100 TCR may be of value in the adoptive immunotherapy of patients with melanoma...
  13. pmc Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions
    Marybeth S Hughes
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 16:457-72. 2005
    ..TCR-transduced T-cells are thus attractive candidates for evaluation in cell transfer therapies of patients with cancer...
  14. pmc Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling
    Chrystal M Paulos
    National Cancer Institute NCI, NIH, Bethesda, Maryland 20892 1502, USA
    J Clin Invest 117:2197-204. 2007
    ..Thus, disruption of the homeostatic balance between the host and microbes can enhance cell-based tumor immunotherapy...
  15. pmc A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas
    William R Burns
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 70:3027-33. 2010
    ..This may represent a novel means to treat the majority of patients with advanced melanoma, most notably those unable to receive current ACT therapies...
  16. doi request reprint Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase
    Timothy L Frankel
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 184:5988-98. 2010
    ..These results suggest that this highly active tyrosinase-specific TCR could be of value in adoptive cell transfer for melanoma...
  17. pmc CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
    Paul A Antony
    Division of Surgery, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:2591-601. 2005
    ..These findings reveal that Th cells can help break tolerance to a persisting self-Ag and treat established tumors through an IL-2-dependent mechanism, but requires simultaneous absence of naturally occurring T(reg) cells to be effective...
  18. pmc Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors
    Michal Lotem
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunother 29:616-27. 2006
    ..These data suggest that DCs transduced with viral vectors may be more efficient than DCs transfected with cDNAs or RNAs for the induction of tumor reactive CD8+ and CD4+ T cells in vitro and in human vaccination trials...
  19. pmc Cancer regression in patients after transfer of genetically engineered lymphocytes
    Richard A Morgan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Science 314:126-9. 2006
    ..This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer...
  20. pmc CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent
    Luca Gattinoni
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Mark O Hatfield Clinical Research Center, 10 Center Drive, Room 3 5750, Bethesda, MD 20892, USA
    Blood 108:3818-23. 2006
    ..These results indicated that CD8(+) CLTA-4(-/-) T-cell-mediated autoimmunity and tumor immunity required CD4(+) T cells in which the function was dysregulated by the absence of CTLA-4-mediated negative costimulation...
  21. pmc Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade
    Ajay V Maker
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA
    J Immunol 175:7746-54. 2005
    ..Therefore, our results suggest that the antitumor effects of CTLA-4 blockade are due to increased T cell activation rather than inhibition or depletion of T regulatory cells...
  22. pmc T-cell receptor gene therapy of established tumors in a murine melanoma model
    John D Abad
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 31:1-6. 2008
    ..This model may be a powerful tool for evaluating future TCR gene transfer-based strategies...
  23. pmc Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer
    Rajeev K Shrimali
    Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1201, USA
    Cancer Res 70:6171-80. 2010
    ..These studies provide a rationale for the exploration of combining antiangiogenic agents with ACT for the treatment of patients with cancer...
  24. pmc IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
    Christian S Hinrichs
    National Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD 20892 1502, USA
    Blood 111:5326-33. 2008
    ..Thus, the efficacy of CD8(+) T cells for adoptive immunotherapy can be influenced by opposing differentiation programs conferred by IL-2 and IL-21, a finding with important implications for the development of cellular cancer therapies...
  25. pmc Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study
    Ajay V Maker
    Surgery Branch, National Cancer Institute, National Institutes of Health, CRC Room 3 3940, 10 Center Drive, MSC 1201, Bethesda, MD 20814, USA
    Ann Surg Oncol 12:1005-16. 2005
    ..In this study, we assessed the antitumor activity and autoimmune toxicity of CTLA-4 blockade in combination with an immune-activating stimulus, interleukin (IL)-2, in patients with metastatic melanoma...
  26. doi request reprint A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity
    Yangbing Zhao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 183:5563-74. 2009
    ..More importantly, PBLs expressing this new version of the 4D5 CAR could not only efficiently lyse the autologous fresh tumor digests, but they could strongly suppress tumor growth in a xenogenic mouse model...
  27. pmc Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma
    Paul F Robbins
    Surgery Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42, Bethesda, MD 20892 7502, USA
    J Immunol 169:6036-47. 2002
    ..These observations provide an impetus to develop strategies directed toward generating HLA class II-restricted tumor-reactive T cells...
  28. pmc Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy
    Christian S Hinrichs
    National Cancer Institute, Bethesda, MD, USA
    Blood 117:808-14. 2011
    ..Thus, these data suggest that naive cells resist terminal differentiation, or "exhaustion," maintain high replicative potential, and therefore may be the superior subset for use in adoptive immunotherapy...
  29. pmc Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma
    Steven A Rosenberg
    Center for Cancer Research, Surgery Branch, National Cancer Institute, National Institute of Health, Building 10, Room 2B42, 10 Center Drive, Bethesda, Maryland 20892, USA
    J Immunother 26:385-93. 2003
    ....
  30. pmc Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein
    Maria R Parkhurst
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1502, USA
    J Immunother 27:79-91. 2004
    ..These results suggest that recombinant tumor-associated proteins may be clinically applicable for the generation of CD4+ T helper cells in active vaccination strategies or adoptive cellular immunotherapies...
  31. pmc Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 175:6169-76. 2005
    ..Further, the induction of even high levels of antitumor T cells may be insufficient to alter tumor progression...
  32. pmc Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
    Mark E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20902, USA
    Science 298:850-4. 2002
    ..This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases...
  33. pmc Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines
    Yangbing Zhao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:4415-23. 2005
    ..These results strongly support the idea that redirection of normal T cell specificity by TCR gene transfer can have potential applications in tumor adoptive immunotherapy...
  34. pmc Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy
    Jianping Huang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 176:7726-35. 2006
    ..004) with the ability of these TILs to mediate tumor regression following adoptive transfer...
  35. pmc Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy
    Juhua Zhou
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 28:53-62. 2005
    ....
  36. pmc Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines
    Franz O Smith
    Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1201, USA
    Clin Cancer Res 14:5610-8. 2008
    ..v. interleukin-2 (IL-2) given either alone or in combination with a variety of melanoma vaccines...
  37. pmc Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma
    Kimberly R Lindsey
    Surgery Branch, National Cancer Institute, Center for Cancer Research, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 12:2526-37. 2006
    ..Two clinical trials were conducted to evaluate the clinical efficacy and immunologic impact of vaccination against the tyrosinase protein plus systemic interleukin 2 (IL-2) administration in patients with advanced metastatic melanoma...
  38. doi request reprint A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors
    Shicheng Yang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 33:648-58. 2010
    ..The methodology described here could be readily applied for engineering CD8+ T cells with antitumor specificity for human adoptive immunotherapy...
  39. pmc Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells
    Claudia Wrzesinski
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Immunother 33:1-7. 2010
    ..Thus, increased intensity lymphodepletion triggers enhanced tumor treatment efficacy and the benefits of high-dose total body irradiation must be titrated against its risks...
  40. pmc Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
    Luca Gattinoni
    Center for Cancer Research, National Cancer Institute NCI, National Institutes of Health NIH, Bethesda, MD 20892, USA
    J Exp Med 202:907-12. 2005
    ..Thus, the restricted availability of homeostatic cytokines can be a contributing factor to peripheral tolerance, as well as a limiting resource for the effectiveness of tumor-specific T cells...
  41. pmc Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application
    Ling Zhang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Immunother 35:430-9. 2012
    ..These results support the clinical application of adoptive transfer of young TIL engineered with the NFAT.hIL12 vector as a new approach for cancer immunotherapy...
  42. pmc IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
    Sid P Kerkar
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    J Clin Invest 121:4746-57. 2011
    ....
  43. pmc Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers
    Andrea Boni
    Clinical Research Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 112:4746-54. 2008
    ..Taken together, these data indicate that the use of tumor-specific allogeneic CD8(+) T cells or CD4(+) can result in significant antitumor effects in the absence of measurable GVHD...
  44. pmc Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunol 177:6527-39. 2006
    ..These studies demonstrate the feasibility and safety of using vaccine-induced PBMC for cell transfer, but suggests that they are not as effective as TIL in adoptive immunotherapy even when transferred into lymphodepleted hosts...
  45. pmc Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression
    Jennifer A Wargo
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 58:383-94. 2009
    ..These results have relevance for TCR-based gene therapies targeting common epithelial malignancies...
  46. pmc Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling
    Yangbing Zhao
    Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1201, USA
    Cancer Res 67:2425-9. 2007
    ..The genetic manipulation of HSCs has broad implications for ACT of cancer...
  47. pmc Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor
    James N Kochenderfer
    Surgery Branch of the National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 32:689-702. 2009
    ....
  48. pmc Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes
    Amelia Grover
    Surgery Branch and Dermatology Branch, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 12:5801-8. 2006
    ..Accumulating evidence from animal models suggests that route of immunization can have a substantial influence on the subsequent migration of primed, activated T cells in vivo...
  49. pmc Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
    Christopher A Klebanoff
    Howard Hughes Medical Institute, National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 102:9571-6. 2005
    ..Thus, tumor-reactive CD8+ T cell populations with the phenotypic and functional attributes of T(CM) may be superior to T(EM)/effector T cells for adoptive immunotherapies using concomitant tumor-antigen vaccination...
  50. pmc Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts
    Sid P Kerkar
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    Cancer Res 70:6725-34. 2010
    ..Our findings reveal an approach to genetically modify T cells to reduce the cell number needed, eliminate the need for vaccines or systemic IL-2, and improve immunotherapy efficacy based on adoptive transfer of gene-engineered T cells...
  51. pmc Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2
    Bianca Heemskerk
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 19:496-510. 2008
    ..In this study, insertion of the IL-2 gene into antitumor TILs increased their ability to survive after IL-2 withdrawal in vitro but did not increase their in vivo persistence or clinical effectiveness...
  52. pmc Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma
    Ajay V Maker
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA
    J Immunother 29:455-63. 2006
    ....
  53. pmc Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene
    Cary Hsu
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 109:5168-77. 2007
    ..It does not appear that the retroviral vector integration sites played a role in the continuous growth of this cell clone, but this remains under investigation...
  54. pmc Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
    Kimberly E Beck
    Surgery Branch and Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Clin Oncol 24:2283-9. 2006
    ..A report on the diagnosis, pathology, treatment, clinical outcome, and significance of the immune-mediated enterocolitis seen with ipilimumab is presented...
  55. pmc CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma
    Peter A Prieto
    Surgery Branch, National Cancer Institute, NIH, Bldg 10 CRC, Room 3 5760, 10 Center Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 18:2039-47. 2012
    ..Treatment with ipilimumab can cause objective tumor responses in patients with metastatic melanoma. We have treated 177 evaluable patients in three clinical trials and have long-term follow-up to evaluate the durability of responses...
  56. pmc Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity
    Douglas C Palmer
    National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 105:8061-6. 2008
    ..These findings have particular importance for immunotherapies directed against self-antigens and highlight the need for targeting unique tumor antigens not expressed in critical tissues...
  57. pmc Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Blood 114:1537-44. 2009
    ..These findings suggest that the tumor microenvironment can lead to up-regulation of PD-1 on tumor-reactive T cells and contribute to impaired antitumor immune responses...
  58. pmc Bcl-2 overexpression enhances tumor-specific T-cell survival
    Jehad Charo
    Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 65:2001-8. 2005
    ..Our data suggest that adoptive immunotherapy approaches to the treatment of cancer patients may be enhanced using Bcl-2-modified tumor-reactive T cells...
  59. pmc Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity
    Christian S Hinrichs
    National Cancer Institute, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 106:17469-74. 2009
    ..These results indicate that insertion of genes that confer antitumor specificity into naïve rather than central memory CD8(+) T cells may allow superior efficacy upon adoptive transfer...
  60. pmc Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1201, USA
    J Immunother 28:403-11. 2005
    ....
  61. pmc Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice
    Dhanalakshmi Chinnasamy
    Surgery Branch, National Cancer Institute, Clinical Research Center, Bethesda, Maryland 20892, USA
    J Clin Invest 120:3953-68. 2010
    ..T cells transduced with VEGFR-2 CAR showed durable and increased tumor infiltration, correlating with their antitumor effect. This approach provides a potential method for the gene therapy of a variety of human cancers...
  62. pmc Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
    Peter Attia
    Surgery Branch, National Cancer Institute, National Institutes of Health, CRC, Room 3W 3940, 10 Center Dr, Bethesda, MD 20892 1201, USA
    J Clin Oncol 23:6043-53. 2005
    ..We have now treated 56 patients to evaluate two different dose schedules of anti-CTLA-4 and to explore the relationship between autoimmunity and tumor regression...
  63. pmc Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma
    Peter Attia
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1201, USA
    J Immunother 28:582-92. 2005
    ..Administration of Denileukin Diftitox does not appear to eliminate regulatory T lymphocytes or cause regression of metastatic melanoma...
  64. pmc Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy
    Khoi Q Tran
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 31:742-51. 2008
    ....
  65. pmc Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
    Mark E Dudley
    Surgery Branch, National Cancer Institute, NIH, CRC 3 3940, 10 Center Dr MSC 1201, Bethesda MD 20892 1202, USA
    J Clin Oncol 23:2346-57. 2005
    ..We investigated the combination of lymphodepleting chemotherapy followed by the adoptive transfer of autologous tumor reactive lymphocytes for the treatment of patients with refractory metastatic melanoma...
  66. pmc Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma
    Juhua Zhou
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 173:7622-9. 2004
    ..A similar analysis may also be useful for monitoring autoimmune responses...
  67. pmc IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells
    Christopher A Klebanoff
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 101:1969-74. 2004
    ..These results provide several avenues for improving adoptive immunotherapy of cancer in patients...
  68. pmc TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:5215-23. 2005
    ....
  69. pmc Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
    Paul F Robbins
    National Institutes of Health, National Cancer Institute, Surgery Branch, Bethesda, MD 20892 1201, USA
    J Clin Oncol 29:917-24. 2011
    ....
  70. pmc Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
    Luca Gattinoni
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    J Clin Invest 115:1616-26. 2005
    ..These findings suggest that the current methodology for selecting T cells for transfer is inadequate and provide new criteria for the generation and the screening of optimal lymphocyte populations for adoptive immunotherapy...
  71. pmc Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
    Richard A Morgan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Ther 18:843-51. 2010
    ..We speculate that the large number of administered cells localized to the lung immediately following infusion and were triggered to release cytokine by the recognition of low levels of ERBB2 on lung epithelial cells...
  72. pmc Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer
    Joseph A Blansfield
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1201, USA
    J Immunother 28:593-8. 2005
    ..The characteristics, clinical course, laboratory values, radiographic findings, and treatment of these 8 patients are the focus of this report...
  73. pmc Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
    Willem W Overwijk
    National Cancer Institute NCI, National Institute of Health, Bethesda, MD 20892 1502, USA
    J Exp Med 198:569-80. 2003
    ....
  74. pmc Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy
    Hung T Khong
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 168:951-6. 2002
    ....
  75. pmc Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1
    Christopher E Touloukian
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 170:1579-85. 2003
    ..Thus, the tumor-bearing state reverses, in part, the tolerance of T cells that results from the normal expression of tissue differentiation Ags...
  76. pmc Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression
    Hung T Khong
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1502, USA
    J Immunother 27:184-90. 2004
    ..This paper thus provides evidence for both the effectiveness of the immune destruction of cancer as well as problems associated with antigen-loss tumor escape mechanisms...
  77. pmc Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination
    Daniel J Powell
    Surgery Branch, National Cancer Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 27:36-47. 2004
    ....
  78. pmc Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes
    Simone Seiter
    Department of Transfusion Medicine, Center for Cancer Research, National Cancer Institute, Building 10, Room 2B42, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Immunother 25:252-63. 2002
    ..These data provide direct enumeration of MART-1/MelanA and gp100/pMel17 reactivity ex vivo and in vitro in the context of HLA-A*0201...
  79. pmc Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine
    Cary Hsu
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 175:7226-34. 2005
    ..In the setting of adoptive cell transfer, IL-15-transduced lymphocytes may prolong lymphocyte survival in vivo and could potentially enhance antitumor activity...
  80. pmc IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 30:294-302. 2007
    ....
  81. pmc Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma
    Steven Yeh
    National Eye Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20814, USA
    Ophthalmology 116:981-989.e1. 2009
    ..To describe the ophthalmic and systemic autoimmune findings after successful adoptive cell transfer of ex vivo expanded, autologous tumor-reactive tumor-infiltrating lymphocytes (TIL) for metastatic melanoma...
  82. pmc Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen
    Hung T Khong
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1502, USA
    J Immunother 27:472-7. 2004
    ..This result raises questions about the use of synthetic peptides derived from NY-ESO-1 as a sole form of immunization...
  83. pmc Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR
    Cyrille J Cohen
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 175:5799-808. 2005
    ..These results suggest that lymphocytes genetically engineered to express anti-p53 TCR may be of value for the adoptive immunotherapy of patients with a variety of common malignancies...
  84. pmc Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes
    Laura A Johnson
    Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunol 177:6548-59. 2006
    ..We propose that inducing expression of this highly avid TCR in patient PBMC has the potential to induce tumor regression, as an "off-the-shelf" reagent for allogeneic melanoma patient gene therapy...
  85. pmc Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells
    Shicheng Yang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 31:830-9. 2008
    ..Compared with gamma-retroviral vectors, the TCR transgene could be preferentially expressed on a less-differentiated cell population...
  86. ncbi request reprint Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities
    John P Riley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Room 2B42, Building 10, 9000 Rockville Pike, Bethesda, MD 20892 1502, USA
    J Immunol Methods 276:103-19. 2003
    ..These results suggest that the use of peptide mixtures may facilitate the identification of new tumor-associated antigens through the application of reverse immunology...
  87. pmc T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product
    Jianping Huang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 172:6057-64. 2004
    ....
  88. doi request reprint Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma
    Franz O Smith
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892 1201, USA
    J Immunother 32:870-4. 2009
    ..Cell proliferation in vitro was further stimulated by additional vaccine and interleukin-2. The patient has an ongoing partial response at 10 months after the last treatment...
  89. pmc CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens
    Luv Ram Javia
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, U S A
    J Immunother 26:85-93. 2003
    ....
  90. pmc Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Immunother 31:189-98. 2008
    ....
  91. pmc Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction
    Stacy E Thurber
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Immunother 25:63-71. 2002
    ....
  92. pmc Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells
    Christian S Hinrichs
    National Cancer Institute NCI, National Institutes of Health NIH, Bethesda, Maryland 20892 1502, USA
    J Immunother 28:517-24. 2005
    ..Finally, because glucocorticoids had no effect on tumor regression in this model, it may be possible to use glucocorticoids in some patients receiving ACT-based immunotherapy regimens...
  93. pmc Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function
    Christopher E Touloukian
    National Cancer Institute, NIH, Building 10, Room 2B42, Bethesda, MD 20892, USA
    Cancer Res 62:5144-7. 2002
    ..These findings indicate that antigens expressed by malignant melanoma cells can partially activate CD4(+) T lymphocytes...
  94. pmc Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes
    Yangbing Zhao
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunother 29:398-406. 2006
    ..Major histocompatibility complex class II TCR-transduced CD4 T cells provides an alternative source of tumor antigen-specific T cells for adoptive immunotherapy of cancer patients...
  95. pmc Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2
    Peter Attia
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 29:208-14. 2006
    ..The short in vivo half-life of LMB-2 makes it an attractive candidate for reducing human T(reg) cells in vivo before the administration of cancer vaccine or cell transfer immunotherapy approaches...
  96. pmc Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation
    William R Burns
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 114:2888-99. 2009
    ..The use of immunomodulatory adjuvants, eg, vaccination or cytokine therapy, for in vivo T-cell activation may help overcome this metabolic quiescence and thus augment cellular immunotherapy-based cancer therapy...
  97. pmc Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression
    Jianping Huang
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland 20892, USA
    J Immunother 28:258-67. 2005
    ....
  98. pmc High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation
    Yangbing Zhao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Mol Ther 13:151-9. 2006
    ..The results of this study indicate that mRNA electroporation provides a powerful tool to introduce genes into both human and murine primary T lymphocytes...
  99. ncbi request reprint Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research
    J Carl Barrett
    National Cancer Institute Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Adv Hematol Oncol 1:302-6. 2003
    ..Its infrastructure supports the iterative flow of information from the bench to the bedside and from the bedside to the bench, expediting the delivery of molecularly based therapeutics to cancer patients...
  100. doi request reprint Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy
    Peter A Prieto
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 33:547-56. 2010
    ..Thus, optimized CD8(+) selection combines the benefits of antigen-selected TIL and young TIL for generating lymphocyte cultures for ACT, and should be evaluated in cell transfer therapy protocols...
  101. pmc Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent
    Ke Liu
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 26:190-201. 2003
    ....